Zobrazeno 31 - 40
of 819
pro vyhledávání: ''
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:1083-1090
There is no standard treatment strategy for patients with extensive-stage small cell lung cancer (SCLC) who have failed two or more prior chemotherapeutic regimens. In this study, we retrospectively evaluated the efficacy and safety of apatinib in pa
Autor:
Michael S. Gordon, Christophe Massard, Vijay V. Upreti, Jürgen Krauss, Erik Rasmussen, Sonal K. Patel, Albert C. Lockhart, H. Henary, Jean-Charles Soria, Gataree Ngarmchamnanrith
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:1057-1063
This study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory clear cell renal cell carcinoma (ccRCC). This was an open-label, adaptive dose-ex
Autor:
Itaru Endo, Kei Sato, Hiroshi Miyamoto, Takashi Kosaka, Sho Sato, Hirotoshi Akiyama, Chikara Kunisaki, Yusaku Tanaka
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:1047-1055
The therapeutic outcomes of stage III gastric cancer patient receiving D2 gastrectomy and adjuvant chemotherapy remain unsatisfactory. To improve the long-term outcomes in this population, the combination of docetaxel and S-1 (DS) therapy can be expe
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:939-949
The impact of pharmacogenetics on predicting survival in gastroenteric cancer remains unclear. We tested 322 consecutive patients treated with capecitabine-based chemotherapy for CDA and MTHFR polymorphisms. Patients who carried the CDA 79 A>C (rs207
Autor:
Martin Johnson, Haiyi Jiang, Mitsuo Higashimori, Fredrik Nyberg, Weifeng Tang, Helen Tomkinson, Yohji Itoh, Yusuke Tanigawara, Toshio Kawata
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:849-858
A prospective, multicenter, large-scale cohort with a nested case–control study (NCT00252759) was conducted to identify and quantify risk factors for interstitial lung disease (ILD) in Japanese patients with non-small-cell lung cancer who received
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:797-802
To explore the clinical significance of plasma D-dimer increase for transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer (PLC).The clinical data of 80 PLC patients who underwent TACE in our hospital from January 2015
Autor:
Takao Takahashi, Kazuhiro Yoshida, Hirotoshi Iihara, Akio Suzuki, Hironori Fujii, Ryo Kobayashi, Chiaki Yoshimi, Nobuhisa Matsuhashi
Publikováno v:
Cancer Chemotherapy and Pharmacology
Background/aim Cholinergic syndrome frequently occurs within the first 24 h after irinotecan injection. We evaluated the prophylactic effect of scopolamine butylbromide on irinotecan-related cholinergic syndrome. Patients and methods Fifty-nine patie
Autor:
Michael A. Maddaus, Mark N. Kirstein, Abeer F. Alharbi, Robert A. Kratzke, Kinjal Sanghavi, Jonathan D'Cunha
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:387-391
PURPOSE: We investigated the safety, pharmacokinetics, and efficacy of gemcitabine administered via bronchial artery infusion (BAI) and IV infusion in advanced NSCLC patients. METHODS: Patients were eligible if they had received at least two prior cy
Autor:
Dorte Nielsen, Estrid Høgdall, P. Grundtvig Sørensen, P. G. Nielsen, A. Fullerton, Iben Kümler, S. Theile, B. Vittrup Jensen, W. Skovrider-Ruminski, J. Palshof
Publikováno v:
Cancer Chemotherapy and Pharmacology
Kümler, I, Sørensen, P G, Palshof, J, Høgdall, E, Skovrider-Ruminski, W, Theile, S, Fullerton, A, Nielsen, P G, Jensen, B V & Nielsen, D L 2019, ' Oral administration of irinotecan in patients with solid tumors : an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics ', Cancer Chemotherapy and Pharmacology, vol. 83, no. 1, pp. 169-178 . https://doi.org/10.1007/s00280-018-3720-7
Kümler, I, Sørensen, P G, Palshof, J, Høgdall, E, Skovrider-Ruminski, W, Theile, S, Fullerton, A, Nielsen, P G, Jensen, B V & Nielsen, D L 2019, ' Oral administration of irinotecan in patients with solid tumors : an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics ', Cancer Chemotherapy and Pharmacology, vol. 83, no. 1, pp. 169-178 . https://doi.org/10.1007/s00280-018-3720-7
Background: Oral drug formulations have several advantages compared to intravenous formulation. Apart from patient convenience and favorable pharmacoeconomics, they offer the possibility of frequent drug administration at home. In this study, we pres
Autor:
Koichi Okamoto, Ichiro Takemasa, Yasushi Sato, Tamotsu Sagawa, Takayuki Nobuoka, Tetsuji Takayama, Koshi Fujikawa, Hiroshi Miyamoto, Masahiro Hirakawa, Hiroyuki Ohnuma, Kyoko Hamaguchi, Yasuo Takahashi, Naoki Muguruma
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:161-167
The aim of this study was to determine the recommended dose (RD) for a docetaxel/oxaliplatin/S-1 (DOS) regimen in patients with unresectable gastric cancer and to preliminarily evaluate its efficacy. Previously untreated patients with histologically